Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body.
There is no cure and no proven treatment for ALS. However, available treatments can help control symptoms, prevent unnecessary complications, and make the patient’s life easier. For most people with ALS, the main treatment may involve the management of symptoms. Supportive care is best provided by multidisciplinary teams of healthcare professionals such as physicians, pharmacists, therapists—physical, occupational, and speech—nutritionists, social workers, respiratory therapists, clinical psychologists, and home care and hospice nurses.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market
The Amyotrophic Lateral Sclerosis (ALS) market report also covers emerging drugs, current treatment practices, Amyotrophic Lateral Sclerosis (ALS) market share of the individual therapies, current and forecasted Amyotrophic Lateral Sclerosis (ALS) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Amyotrophic Lateral Sclerosis (ALS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Amyotrophic Lateral Sclerosis (ALS) Market Key Facts
-
The prevalent population of Amyotrophic lateral sclerosis (ALS) in the seven major markets was 71,628 in 2020 and is expected to grow at a CAGR of 0.6% during the study period (2018-2030).
-
The diagnosed prevalent cases of ALS, in the United States, were 18,824 in 2020.
-
In 2020, the patients with the limb site of onset accounted for 2,502 cases, followed by 1,251 cases with the bulbar site of onset, 801 cases with a cervical site of onset, and 450 cases with other uncertain regions in Germany.
-
The prevalence of Amyotrophic lateral sclerosis (ALS) is more common in males than in females. The diagnosed prevalent cases of ALS in males and females in the United States were 11,482 and 7,341 in 2020.
Key Benefits of Amyotrophic Lateral Sclerosis (ALS) Market Report
-
Amyotrophic Lateral Sclerosis (ALS) market report provides an in-depth analysis of Amyotrophic Lateral Sclerosis (ALS) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Amyotrophic Lateral Sclerosis (ALS) market report will help in developing business strategies by understanding the Amyotrophic Lateral Sclerosis (ALS) Market trends & developments, key players, and future market competition that will shape and drive the Amyotrophic Lateral Sclerosis (ALS) market in the upcoming years.
-
The Amyotrophic Lateral Sclerosis (ALS) market report covers Amyotrophic Lateral Sclerosis (ALS) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Amyotrophic Lateral Sclerosis (ALS) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Amyotrophic Lateral Sclerosis (ALS) Market
Amyotrophic lateral sclerosis (ALS) market size is expected to increase during the forecast owing to the rise in the number of diagnosed prevalent cases in the 7MM. Similarly, the current therapeutic landscape of Amyotrophic lateral sclerosis (ALS) in the United States is driven by current treatment practices and the expected launch of emerging therapies.
The market size of Amyotrophic lateral sclerosis (ALS) in the seven major markets was USD 401.19 Million in 2020, which is expected to grow during the study period.
The Amyotrophic Lateral Sclerosis (ALS) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Amyotrophic Lateral Sclerosis (ALS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Amyotrophic Lateral Sclerosis (ALS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Amyotrophic Lateral Sclerosis (ALS) Epidemiology
The Amyotrophic Lateral Sclerosis (ALS) epidemiology section covers insights about the historical and current Amyotrophic Lateral Sclerosis (ALS) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Amyotrophic Lateral Sclerosis (ALS) Drugs Uptake and Key Market Players
The Amyotrophic Lateral Sclerosis (ALS) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Amyotrophic Lateral Sclerosis (ALS) market or expected to get launched in the market during the study period. The analysis covers Amyotrophic Lateral Sclerosis (ALS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Amyotrophic lateral sclerosis (ALS) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also the expected launch of emerging therapies during the forecasted period.
Amyotrophic lateral sclerosis (ALS) Companies:
Orphazyme
Orion Pharma
Brainstorm Cell Therapeutics
Biogen
AB Science
Ionis Pharmaceuticals
Clene Nanomedicine
Neurosense therapeutics
Amylyx
MediciNova
Biohaven Pharmaceuticals
Prilenia Therapeutics
And many others.
Amyotrophic lateral sclerosis (ALS) Therapies covered in the report include:
ODM-109
Arimoclomol
Reldesemtiv
Verdiperstat
NurOwn
IC14
BIIB067
CNM-Au8
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Amyotrophic Lateral Sclerosis (ALS) Competitive Intelligence Analysis
4. Amyotrophic Lateral Sclerosis (ALS) Market Overview at a Glance
5. Amyotrophic Lateral Sclerosis (ALS) Disease Background and Overview
6. Amyotrophic Lateral Sclerosis (ALS) Patient Journey
7. Amyotrophic Lateral Sclerosis (ALS) Epidemiology and Patient Population
8. Amyotrophic Lateral Sclerosis (ALS) Treatment Algorithm, Current Treatment, and Medical Practices
9. Amyotrophic Lateral Sclerosis (ALS) Unmet Needs
10. Key Endpoints of Amyotrophic Lateral Sclerosis (ALS) Treatment
11. Amyotrophic Lateral Sclerosis (ALS) Marketed Products
12. Amyotrophic Lateral Sclerosis (ALS) Emerging Therapies
13. Amyotrophic Lateral Sclerosis (ALS) Seven Major Market Analysis
14. Attribute Analysis
15. Amyotrophic Lateral Sclerosis (ALS) Market Outlook (7 major markets)
16. Amyotrophic Lateral Sclerosis (ALS) Access and Reimbursement Overview
17. KOL Views on the Amyotrophic Lateral Sclerosis (ALS) Market.
18. Amyotrophic Lateral Sclerosis (ALS) Market Drivers
19. Amyotrophic Lateral Sclerosis (ALS) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports
Amyotrophic lateral sclerosis (ALS) Pipeline Insights
Amyotrophic lateral sclerosis (ALS) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Amyotrophic lateral sclerosis (ALS) market.
BioPharma Blogs – Artificial Intelligence (AI) In Healthcare
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/